莫美替尼治疗骨髓纤维化患者的总生存期:SIMPLIFY-1和SIMPLIFY-2三期试验分析
本文报告SIMPLIFY-1和SIMPLIFY-2两项三期试验中莫美替尼治疗骨髓纤维化的成熟总生存期(OS)和无白血病生存期(LFS),并回顾性分析基线特征及疗效终点与OS的关联。结果显示两试验中生存分布相似,基线输血独立性与改善生存相关。
要点
- SIMPLIFY-1中莫美替尼组与芦可替尼后莫美替尼组OS和LFS相似。
- SIMPLIFY-2中莫美替尼组与最佳可用治疗后莫美替尼组OS和LFS相似。
- 两项研究中基线输血独立性均与改善生存相关。
核心结论
- 在SIMPLIFY-1和SIMPLIFY-2中,莫美替尼方案与对照方案的生存分布相似。
- 基线输血独立性与改善生存相关,第24周输血独立性应答与改善OS相关。
研究设计与样本
- SIMPLIFY-1和SIMPLIFY-2为三期试验,本文报告成熟OS和LFS及回顾性分析。
- SIMPLIFY-1纳入未接受过JAK抑制剂的患者,随机分配至莫美替尼组或芦可替尼后莫美替尼组。
- SIMPLIFY-2纳入接受过芦可替尼的患者,随机分配至莫美替尼组或最佳可用治疗后莫美替尼组。
主要发现
- SIMPLIFY-1中,莫美替尼组2年OS为81.6%、LFS为80.7%,芦可替尼后莫美替尼组2年OS为80.6%、LFS为79.3%。
- SIMPLIFY-2中,莫美替尼组2年OS为65.8%、LFS为64.2%,最佳可用治疗后莫美替尼组2年OS为61.2%、LFS为59.7%。
- 两项研究中基线输血独立性与改善生存相关(SIMPLIFY-1 HR=0.474,p=0.0001;SIMPLIFY-2 HR=0.226,p=0.0005)。
关键数值与推荐
- SIMPLIFY-1中未接受过JAK抑制剂且随机分配至莫美替尼的患者,第24周输血独立性应答与改善OS相关:单变量分析HR=0.323(p<0.0001),多变量分析HR=0.311(p<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Janus kinase inhibitors (JAKi) approved for myelofibrosis provide spleen and symptom improvements but do not address anemia, a negative prognostic factor. Momelotinib, an inhibitor of ACVR1/ALK2, JAK1 and JAK2, demonstrated activity against anemia, symptoms, and splenomegaly in the phase 3 SIMPLIFY trials. Here, we report mature overall survival (OS) and leukemia-free survival (LFS) from both studies, and retrospective analyses of baseline characteristics and efficacy endpoints for OS associations. Survival distributions were similar between JAKi-naïve patients randomized to momelotinib, or ruxolitinib then momelotinib, in SIMPLIFY-1 (OS HR = 1.02 [0.73, 1.43]; LFS HR = 1.08 [0.78, 1.50]). Two-year OS and LFS were 81.6% and 80.7% with momelotinib and 80.6% and 79.3% with ruxolitinib then momelotinib. In ruxolitinib-exposed patients in SIMPLIFY-2, two-year OS and LFS were 65.8% and 64.2% with momelotinib and 61.2% and 59.7% with best available therapy then momelotinib (OS HR = 0.98 [0.59, 1.62]; LFS HR = 0.97 [0.59, 1.60]). Baseline transfusion independence (TI) was associated with improved survival in both studies (SIMPLIFY-1 HR = 0.474, p = 0.0001; SIMPLIFY-2 HR = 0.226, p = 0.0005). Week 24 TI response in JAKi-naïve, momelotinib-randomized patients was associated with improved OS in univariate (HR = 0.323; p < 0.0001) and multivariate (HR = 0.311; p < 0.0001) analyses. These findings underscore the importance of achieving or maintaining TI in myelofibrosis, supporting the clinical relevance of momelotinib's pro-erythropoietic mechanism of action, and potentially informing treatment decision-making.
引用
- Mesa R, Harrison C, Oh ST, et al. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia. 2022. PMID: 35869266. doi:10.1038/s41375-022-01637-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。